The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

III.a

Alveolar hemorrhage (AH), diffuse AH (DAH)

Publications

Bianco A, Mari PV, Larici AR, Lucchini M, Nociti V, Losavio FA, De Fino C, Cicchetti G, Coraci D, Richeldi L, Mirabella M

Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients.

Multiple sclerosis and related disorders. 2020;37:101450

Myro AZ, Bjerke G, Zarnovicky S, Holmøy T

Diffuse alveolar hemorrhage during alemtuzumab infusion in a patient with multiple sclerosis: a case report.

BMC pharmacology & toxicology. 2018;19(1):75

Tahir W, Hakeem A, Baker R, Ahmad N

Diffuse Alveolar haemorrhage: a fatal complication after alemtuzumab induction therapy in renal transplantation.

Transplantation proceedings. 2015;47(1):151-4

Sachdeva A, Matuschak GM

Diffuse alveolar hemorrhage following alemtuzumab.

Chest. 2008;133(6):1476-1478